MIRA · Mira Pharmaceuticals, Inc. · Executive Compensation
$0.64
+0.01 (+1.55%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of filing this Quarterly Report on Form 10-Q, the Company has not generated revenues, continued to generate losses, and has insufficient cash and cash equivalents on hand to support its operations for at least the 12 months following the date these unaudited condensed financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Quarterly Report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$26.57M
Shares
42.02M
Volume · Oct 19
66.06K
Avg daily vol (3M)
578.98K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO | $5,304,174 |
| Michelle Yanez | Former CFO | $116,712 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO | $3,140,263 |
| Michelle Yanez | Former CFO | $444,021 |
| Former CFO | — | — |
| Alan Weichselbaum | Former CFO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO ^^ | $1,665,564 |
| Michelle Yanez | CFO ^^ | $541,624 |
| Adam Kaplin | former President & CSO ^^ | $199,600 |
| Jim McNulty | former CFO | $154,000 |
| Jude Uzonwanne | former CEO ^^ | $81,569 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jude Uzonwanne | former CEO ^^ | $922,385 |
| Adam Kaplin | former President & CSO ^^ | $789,001 |
| Jim McNulty | former CFO | $366,869 |
| Erez Aminov | CEO ^^ | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andriy Mushak | fractional Chief Financial Officer | Appointed | 2026-06-08 |
| Edward MacPherson | directors of the Company | Appointed | 2025-09-11 |
| Matthew Whalen | directors of the Company | Appointed | 2025-09-11 |
| Matthew Del Giudice, M.D. | directors of the Company | Appointed | 2025-09-11 |
| Denil Nanji Shekhat, M.D. | directors of the Company | Appointed | 2025-09-11 |
| Erez Aminov | directors of the Company | Appointed | 2025-09-11 |
| Alan Weichselbaum | Chief Financial Officer | Appointed | 2025-05-21 |
| Michelle Yanez | Chief Financial Officer, Treasurer and Secretary | Resigned | 2025-05-21 |
| Matthew Pratt Whalen | member of the Board and Chairman of the Company's Audit Committee | Appointed | 2024-11-21 |
| Michael Jerman | member of the Board | Resigned | 2024-11-21 |
| Adam Kaplin | President and Chief Scientific Officer | Resigned | 2024-03-13 |
| Ned MacPherson | member of the Board | Appointed | 2024-03-13 |
| Erez Aminov | Chairman of the Board | Appointed | 2024-03-13 |
| Matthew P. Del Giudice | member of the Board | Appointed | 2024-03-13 |
| Denil N. Shekhat | member of the Board | Appointed | 2024-03-13 |
| Hugh McColl | Board | Resigned | 2024-03-13 |
| Chris Chapman | Executive Chairman | Resigned | 2024-03-13 |
| Brad Kroenig | Board | Resigned | 2024-03-13 |
| Talhia Tuck | Board | Resigned | 2024-03-13 |
| Christos Nicholoudis, Esq. | part-time General Counsel | Resigned | 2024-01-17 |
| Christos Nicholoudis, Esq. | Board of Directors | Resigned | 2024-01-17 |
| Brian Daly | Board of Directors | Resigned | 2023-12-01 |
| Michael Jerman | Chairman of the Audit Committee of the Board | Appointed | 2023-12-01 |
| Michael Jerman | Director | Appointed | 2023-11-20 |
| David Vorhoff | Board of Directors | Resigned | 2023-10-25 |
Leadership
- Erez Aminov CEO, Chairman, Board Member
- Jude Uzonwanne CEO
- Michael Jerman Chairman, Board Member
- Alan Weichselbaum CFO
- Andriy Mushak CFO
- Jim McNulty CFO
- Brian Daly Board Member
- Denil N. Shekhat Board Member
- Denil Nanji Shekhat Board Member
- Denil Nanji Shekhat, M.D. Board Member
- Edward MacPherson Board Member
- Matthew Del Giudice, M.D. Board Member
- Matthew P. Del Giudice Board Member
- Matthew Paul Del Giudice Board Member
- Matthew Pratt Whalen Board Member
- Matthew Whalen Board Member
- Ned MacPherson Board Member